Community Oriented Tool for Reducing Melanoma Health Disparities

减少黑色素瘤健康差异的面向社区的工具

• 批准号: 8303053
• 负责人: Eric R. Craine
• 金额: $ 19.64万
• 依托单位: WESTERN RESEARCH COMPANY, INC.
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-01 至 2013-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8303053
• 关键词: Address; Affect; Archives; Awareness; Biopsy; Communities; Data; Data Collection; Development; Digital Photography; Disease; Early Diagnosis; Education; Education and Outreach; Evaluation; Foundations; Frequencies; Goals; Grant; Hand; Health; Healthcare; Hispanics; Home environment; Image; Imaging technology; Insurance; Language; Lesion; Literature; Malignant Neoplasms; Manuscripts; Medical; Mole the mammal; Outcome; Patients; Phase; Physicians; Pigments; Population; Preparation; Process; Protocols documentation; Public Health; Qualitative Research; Research; Resources; Risk; Screening procedure; Self Perception; Skin; Staging; System; Technology; Translations; United States National Center for Health Statistics; United States National Institutes of Health; combat; compliance behavior; efficacy evaluation; efficacy research; follow-up; health disparity; improved; innovation; melanoma; mortality; programs; tool

DESCRIPTION (provided by applicant): Melanoma is a frequently fatal cancer that, if detected early, is relatively easily cured. This disease is rapidly increasing in frequency and has recently been identified by the National Center for Health Statistics Health Disparities Study as a high profile health disparity. Further it has been noted to occur more frequently now in both young people and Hispanic populations. We have developed a unique, proprietary and innovative self-screening imaging technology (DermAlert) that has the potential to significantly mitigate disparate melanoma outcomes by more fully involving people at-risk of melanoma in their own healthcare, and by enabling much earlier detection of new and changed pigmented lesions that may be early melanomas. The goal of this NIH grant program is to address key issues (patient related causes for the disparity and physician/insurance requirements for efficacy demonstration) for the translation of this technology into the at- risk community to realize reduction in melanoma disparity. We propose a program to research the efficacy of DermAlert imaging self screening for new and changed pigmented lesions, and to provide education that will be useful in overcoming barriers to use of the DermAlert system in affected populations. Phase I activities will include: " Conversion of DermAlert to a Spanish language resource, " Analysis of specific classes of barriers to use of imaging by groups suffering melanoma health disparities, " Development of education and outreach tools to help overcome barriers to use of self imaging screening, " Preliminary evaluation of the effect of DermAlert use on health outcomes, and " Preparation for an expanded, large scale efficacy study during Phase II. As pigmented lesions, for which change was detected by the imaging system, are biopsied, the results of those biopsies will be tabulated and statistically compared with control set of biopsies for which imaging was not a motivating factor. Using this approach it will be possible to investigate not only patient compliance in the use of the imaging system, but also its utility in helping to guide more effective biopsy decisions. This part of the project will address its efficacy and the resultant medical outcomes Measureable milestones during Phase I include the following, which can be used to help assess the viability of progressing to Phase II research: " Qualitative and quantitative identification of specific barriers to imaging that contribute to the health disparity " Preparation of an educational video for helping patients and physicians overcome barriers to use of this technology, and " Foundation and preliminary analysis of an archive of follow-up biopsy data for evaluation of efficacy of using DermAlert. Successful completion of the project will result in enhanced awareness and reduced barriers to use of a completely unique imaging protocols which will more deeply involve patients in their personal health care, contribute to earlier detection of potential melanomas, and have the power to ultimately reduce the number of unnecessary biopsies and reduce patient mortality at the hands of a serious health disparity.

描述（由申请人提供）：黑色素瘤是一种经常致命的癌症，如果早期发现，相对容易治愈。这种疾病的发病率正在迅速增加，最近被国家卫生统计中心的健康差异研究确定为一种引人注目的健康差异。此外，它已经注意到现在更频繁地发生在年轻人和西班牙裔人口中。 我们开发了一种独特的、专有的和创新的自我筛查成像技术（DermAlert），该技术有可能通过更充分地让有黑色素瘤风险的人参与他们自己的医疗保健，并通过更早地检测可能是早期黑色素瘤的新的和变化的色素性病变，来显著减轻不同的黑色素瘤结果。该NIH资助项目的目标是解决关键问题（差异的患者相关原因和有效性证明的医生/保险要求），以便将该技术转化为风险社区，从而减少黑色素瘤差异。 我们提出了一个计划，研究DermAlert成像自我筛查新的和改变色素性病变的疗效，并提供教育，这将是有用的，在受影响的人群中使用DermAlert系统的障碍。 第一阶段的活动将包括：“将DermAlert转换为西班牙语资源“，分析患有黑色素瘤健康差异的群体使用成像的特定类别障碍，“开发教育和外展工具以帮助克服使用自我成像筛查的障碍“，初步评估DermAlert使用对健康结果的影响，以及“准备扩大，II期大规模疗效研究。 当对成像系统检测到变化的色素性病变进行活检时，将对这些活检的结果进行制表，并与成像不是激励因素的活检对照组进行统计学比较。使用这种方法，不仅可以调查患者在使用成像系统时的依从性，还可以调查其在帮助指导更有效的活检决策方面的效用。该项目的这一部分将讨论其疗效和由此产生的医疗结果。第一阶段期间可衡量的里程碑包括以下内容，可用于帮助评估进展到第二阶段研究的可行性：“定性和定量识别导致健康差异的成像特定障碍”准备一个教育视频，帮助患者和医生克服使用该技术的障碍，以及“建立和初步分析随访活检数据档案，以评估使用DermAlert的有效性。 该项目的成功完成将提高人们的认识，减少使用完全独特的成像协议的障碍，这将使患者更深入地参与其个人医疗保健，有助于早期发现潜在的黑色素瘤，并有能力最终减少不必要的活检数量，降低患者在严重健康差异下的死亡率。